Tavneos Rare Disease Drug Recalled in Ireland Following EMA Safety Review
The rare autoimmune disease medication Tavneos has been officially recalled from shelves across the Republic of Ireland following a European Medicines Agency safety review, leaving approximately 60 patients and their prescribing consultants. According to RTÉ and subsequent reporting by the UK Pulse, the Health Products Regulatory Authority requested a wholesale-level recall of the drug after European regulators stripped its market authorization over severe safety concerns.
Avacopan, marketed globally under the brand name Tavneos, targets adults with severe and rare autoimmune conditions that trigger inflammation of the blood vessel walls. Specifically, the drug was authorized in Ireland for patients suffering from severe active granulomatosis with polyangiitis or microscopic polyangiitis. Prior to the regulatory intervention, about 60 individuals in the country relied on the treatment, prescribed exclusively by consultants possessing specialist experience in management of these conditions.
The regulatory domino effect began in May when Kissei Pharmaceutical, which sells the drug in Japan, disclosed a safety signal. According to RTÉ, Kissei reported that 20 deaths had occurred among more than 8,500 patients treated with the medication in Japan since 2022. The Japanese distributor warned prescribing physicians regarding the risk of severe liver dysfunction, prompting calls to stop prescribing it. US-based biotech manufacturer Amgen subsequently clarified that the fatality figures included cases where a direct causal relationship with the drug could not be determined.
Regulatory Crackdown Across European Jurisdictions
The mounting safety data forced a reassessment by continental watchdogs. In June, the European Medicines Agency warned that the therapeutic benefits of Tavneos “no longer proven to outweigh its risks”. The agency finalized a recommendation in July to revoke the product’s market authorization entirely, a motion formally endorsed by the European Commission in early August. This decision triggered compliance measures throughout member states.
In Ireland, wholesale distribution of Tavneos halted on August 11. The Health Products Regulatory Authority followed up by requesting the removal of any remaining stock held at the wholesale level. Neighboring jurisdictions mirrored the move. France’s national medicines safety agency announced that all batches of Tavneos would be pulled from domestic shelves. Meanwhile, the United States Food and Drug Administration offered Amgen the option of a voluntary market withdrawal. When the manufacturer declined, a procedure is underway to determine whether they will be forced to pull the drug.
Clinical Guidance and Patient Continuity
Medical authorities have moved quickly to manage the transition for active patients. The Health Products Regulatory Authority emphasized that patients currently taking Tavneos must not discontinue their regimen without first consulting their healthcare providers. Because the underlying autoimmune conditions are aggressive and dangerous, abrupt cessation without a mapped therapeutic alternative poses a severe clinical risk. Some specialist consultants in Ireland had already made the decision to take patients off this drug.
Market participants monitoring the biotechnology sector will watch closely to see how Amgen manages ongoing regulatory friction in the United States and whether additional international markets follow the European trajectory.